News from intarcia therapeutics, inc. A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Sep 17, 2009, 07:00 ET
A F INTARCIA THERAPEUTICS LOGO INTARCIA THERAPEUTICS LOGO

Intarcia logo. (PRNewsFoto/Intarcia)[KG]
 HAYWARD, CA UNITED STATES
 03/01/2005

Intarcia Therapeutics, Inc. Commences Enrollment of ITCA 650 Phase 2 Study in Type 2 Diabetes

Intarcia Therapeutics, Inc. today announced the start of enrollment for a phase 2 study comparing its proprietary drug candidate ITCA 650...

Jun 08, 2009, 08:44 ET
A F INTARCIA THERAPEUTICS LOGO INTARCIA THERAPEUTICS LOGO

Intarcia logo. (PRNewsFoto/Intarcia)[KG]
 HAYWARD, CA UNITED STATES
 03/01/2005

Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions

DUROS(R) continuous delivery of exenatide produces impressive reductions in fasting plasma glucose, HbA1c and body weight during 28-day...

May 27, 2009, 10:46 ET
A F INTARCIA THERAPEUTICS LOGO INTARCIA THERAPEUTICS LOGO

Intarcia logo. (PRNewsFoto/Intarcia)[KG]
 HAYWARD, CA UNITED STATES
 03/01/2005

Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions

First clinical study evaluating DUROS(R) continuous delivery of exenatide for the treatment of type 2 diabetes Intarcia Therapeutics, Inc. today...

Apr 24, 2009, 10:00 ET
A F INTARCIA THERAPEUTICS LOGO INTARCIA THERAPEUTICS LOGO

Intarcia logo. (PRNewsFoto/Intarcia)[KG]
 HAYWARD, CA UNITED STATES
 03/01/2005

Intarcia Therapeutics, Inc. Announces Completion of Enrollment of ITCA 650 Phase 1b Study for the Treatment of Type 2 Diabetes

First study evaluating DUROS(R) continuous delivery of exenatide for the treatment of type 2 diabetes Intarcia Therapeutics, Inc. today announced...

Jun 06, 2007, 01:00 ET
A F INTARCIA THERAPEUTICS LOGO INTARCIA THERAPEUTICS LOGO

Intarcia logo. (PRNewsFoto/Intarcia)[KG]
 HAYWARD, CA UNITED STATES
 03/01/2005

FierceBiotech Names Intarcia Therapeutics as One of the 'Fierce 15' Biotech Companies of 2007

EMERYVILLE, Calif., June 6 /PRNewswire/ -- Intarcia Therapeutics, Inc. announced today that it has been named to the annual FierceBiotech...

May 21, 2007, 01:00 ET
A F INTARCIA THERAPEUTICS LOGO INTARCIA THERAPEUTICS LOGO

Intarcia logo. (PRNewsFoto/Intarcia)[KG]
 HAYWARD, CA UNITED STATES
 03/01/2005

Intarcia Therapeutics Announces Presentation of Final Results From a Phase 2 Combination Study for the Treatment of Hepatitis C at the Digestive Disease Week Conference

WASHINGTON, May 21 /PRNewswire/ -- Intarcia Therapeutics, Inc., a privately held biopharmaceutical company, today announced the presentation of...

Apr 12, 2007, 01:00 ET

Intarcia Therapeutics Announces Final Results From a Phase 2 Study of Injectable Omega Interferon plus Ribavirin for the Treatment of Hepatitis C Genotype-1

BARCELONA, Spain, April 12 /PRNewswire/ -- Intarcia Therapeutics, Inc., a privately held biopharmaceutical company, today announced final...

Mar 19, 2007, 01:00 ET
A F INTARCIA THERAPEUTICS LOGO INTARCIA THERAPEUTICS LOGO

Intarcia logo. (PRNewsFoto/Intarcia)[KG]
 HAYWARD, CA UNITED STATES
 03/01/2005

Intarcia Raises $50 Million in a Series BB Financing

EMERYVILLE, Calif., March 19 /PRNewswire/ -- Intarcia Therapeutics, Inc., a privately held biopharmaceutical company, announced today the...

Jan 04, 2006, 00:00 ET
A F INTARCIA THERAPEUTICS LOGO INTARCIA THERAPEUTICS LOGO

Intarcia logo. (PRNewsFoto/Intarcia)[KG]
 HAYWARD, CA UNITED STATES
 03/01/2005

Intarcia Therapeutics to Present at the 24th Annual JPMorgan Healthcare Conference

SAN FRANCISCO, Jan. 4 /PRNewswire/ -- Intarcia Therapeutics, Inc., a privately held, biopharmaceutical company, today announced that it will...

Sep 21, 2005, 01:00 ET
A F INTARCIA THERAPEUTICS LOGO INTARCIA THERAPEUTICS LOGO

Intarcia logo. (PRNewsFoto/Intarcia)[KG]
 HAYWARD, CA UNITED STATES
 03/01/2005

Intarcia Therapeutics Will Withdraw Initial Public Offering

EMERYVILLE, Calif., Sept. 21 /PRNewswire/ -- Intarcia Therapeutics, Inc. announced today that it will be requesting the withdrawal of its...

Feb 25, 2005, 00:00 ET

Intarcia Therapeutics Announces Its Phase 3 Clinical Trial for Advanced Breast Cancer

EMERYVILLE, Calif., Feb. 25 /PRNewswire/ -- Intarcia Therapeutics, Inc., a privately held, biopharmaceutical company, initiated its CAT...

Feb 07, 2005, 00:00 ET

- Intarcia Therapeutics Files Registration Statement for Initial Public Offering -

EMERYVILLE, Calif., Feb. 7 /PRNewswire/ -- Intarcia Therapeutics Inc., a privately held biopharmaceutical company, today announced that it has...

Dec 01, 2004, 00:00 ET

Intarcia Closes $50M Private Financing

EMERYVILLE, Calif., Dec. 1 /PRNewswire/ -- Intarcia Therapeutics Inc., a privately held biopharmaceutical company, today announced that it has...

Sep 28, 2004, 01:00 ET

Intarcia Therapeutics (Formerly BioMedicines) to Present at UBS Global Life Sciences Conference on September 28, 2004

EMERYVILLE, Calif., Sept. 28 /PRNewswire/ -- Intarcia Therapeutics, Inc., a leading developer of therapies for patients with cancer,...

Sep 27, 2004, 01:00 ET

BioMedicines, Inc. Announces Name Change to Intarcia Therapeutics, Inc.

EMERYVILLE, Calif., Sept. 27 /PRNewswire/ -- BioMedicines, Inc., a leading developer of therapies for patients with cancer, immunological, and...